The BE SURE study is one of six ongoing clinical trials of bimekizumab...
Aegle Therapeutics raises funds for DEB skin disorder clinical trial
Biotechnology firm Aegle Therapeutics, which specialises in isolating extracellular vesicles (EVs) secreted by mesenchymal stem cells as therapy, has raised $4m in a funding round led by Boca Raton-based New World Angels.
UCB’s bimekizumab outperforms AbbVie’s Humira in psoriasis patients
The BE SURE study is one of six ongoing clinical trials of bimekizumab in psoriasis and is UCB’s third study that has shown positive results this year.
LEO Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal trials
Anti-interleukin-13 is in development for the treatment of moderate-to-severe atopic dermatitis.
FDA and NCATS launch CURE ID app for healthcare professionals
The US Food and Drug Administration (FDA) and the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS) have launched a new app called CURE ID for health care professionals.
Future of IL-33 inhibition in atopic dermatitis in doubt
AnaptysBio's etokimab failed to meet its primary endpoint in a Phase IIb study.
Novartis’ Cosentyx sees mixed results from head-to-head with Humira
Although Novartis' Cosentyx showed numerically higher results for its primary endpoint, it failed to demonstrate statistically significant superiority over AbbVie's Humira.
Pfizer unveils top-line Phase III results for abrocitinib study
Atopic dermatitis is a chronic skin disease characterised by inflammation and skin barrier defects that affects up to 10% of adults and up to 20% of children worldwide.
Taltz knocks down Tremfya in head-to-head trial in psoriasis patients
Patients treated with Taltz demonstrated statistically significantly higher improvements than those treated with Tremfya as measured by PASI 100 at Week 12.
Pfizer’s abrocitinib meets all endpoints in JADE MONO-1 study
Pfizer has reported positive results from the Phase III JADE MONO-1 clinical trial of its investigational Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients with moderate to severe atopic dermatitis.